Latest period
$233.96M
YoY change
+107.1%
5Y CAGR
-4.5%
Peak year (2021)
$211.91M
Latest annual
$93.01M
Cash on Hand history chart for Relmada Therapeutics (RLMD) from 2012 to 2025
Latest: $93.01M
Cash on Hand growth chart for Relmada Therapeutics (RLMD) from 2012 to 2025
Latest: +107.1%
Cash on Hand history table for Relmada Therapeutics (RLMD) from 2012 to 2025
| 2025 | $93.01M | +107.1% | +$48.10M | ||
| 2024 | $44.91M | -53.4% | −$51.41M | ||
| 2023 | $96.32M | -35.1% | −$52.00M | ||
| 2022 | $148.32M | -30.0% | −$63.59M | ||
| 2021 | $211.91M | +81.0% | +$94.82M | ||
| 2020 | $117.09M | +0.6% | +$647.92K | ||
| 2019 | $116.44M | +1163.4% | +$107.23M | ||
| 2018 | $9.22M | +311.6% | +$6.98M | ||
| 2017 | $2.24M | +30.9% | +$528.43K | ||
| 2016 | $1.71M | -79.9% | −$6.79M | ||
| 2015 | $8.50M | -62.2% | −$13.97M | ||
| 2014 | $22.47M | -12.1% | −$3.09M | ||
| 2013 | $25.56M | +285567.1% | +$25.56M | ||
| 2012 | $8.95K | — | — |
- 2025$93.01M+107.1%
- 2024$44.91M-53.4%
- 2023$96.32M-35.1%
- 2022$148.32M-30.0%
- 2021$211.91M+81.0%
- 2020$117.09M+0.6%
- 2019$116.44M+1163.4%
- 2018$9.22M+311.6%
- 2017$2.24M+30.9%
- 2016$1.71M-79.9%
- 2015$8.50M-62.2%
- 2014$22.47M-12.1%
- 2013$25.56M+285567.1%
- 2012$8.95K—
Cash on Hand values are taken from Relmada Therapeutics's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Cash on Hand at Relmada Therapeutics (RLMD)
According to Relmada Therapeutics's latest reported financial statements, the company's latest reported cash and short-term investments is $233.96M. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for net leverage and total assets for the share of assets held in cash.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
In 2025, Relmada Therapeutics (RLMD) cash and short-term investments totalled $93.01M – surged 107.1% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Relmada Therapeutics cash and short-term investments compounded at -4.5% per year, with a net decline across the window.
Relmada Therapeutics cash and short-term investments peaked at $211.91M in 2021; the latest annual figure is $93.01M in 2025 (56.1% below peak).
The highest annual cash and short-term investments of $211.91M was reported in 2021. The lowest in the available history was $8.95K in 2012.
Relmada Therapeutics Cash on Hand by Year
Relmada Therapeutics Cash on Hand 2025: $93.01M
2025's cash and short-term investments for Relmada Therapeutics came in at $93.01M, surged 107.1% from 2024.
Relmada Therapeutics Cash on Hand 2024: $44.91M
Relmada Therapeutics posted cash and short-term investments of $44.91M in 2024, plunged 53.4% below 2023.
Relmada Therapeutics Cash on Hand 2023: $96.32M
In 2023, Relmada Therapeutics reported cash and short-term investments of $96.32M, plunged 35.1% below 2022.
Relmada Therapeutics Cash on Hand 2022: $148.32M
Relmada Therapeutics cash and short-term investments in 2022 was $148.32M, plunged 30.0% below 2021.
Relmada Therapeutics Cash on Hand 2021: $211.91M
Relmada Therapeutics cash and short-term investments in 2021 was $211.91M.
See more financial history for Relmada Therapeutics (RLMD).
Sector peers by Cash on Hand
Healthcare peers of Relmada Therapeutics (RLMD), ranked by their latest cash and short-term investments
| $28.12B | |
| $20.10B | |
| $14.56B | |
| $9.13B | |
| $7.27B | |
| $5.74B | |
| $5.26B | |
| $4.24B |
- $28.12B
- $20.10B
- $14.56B
- $9.13B
- $7.27B
- $5.74B
- $5.26B
- $4.24B
Frequently asked questions
Relmada Therapeutics (RLMD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation